Eli Lilly and Co launched the diabetes and weight loss drug Mounjaro in India on Thursday, defeating competitor Novo-Nordisk A/S, entering the world's most populous country, India, which is currently struggling to address the rising rates of obesity and diabetes within its population. The innovative weight loss medications from Eli Lilly and Co in the USA and Novo-Nordisk A/S in Denmark are experiencing a surge in global demand, and investor interest has also driven up the pharmaceutical companies' valuations.
Clear
All
Quotes
News
Learn
Help
All
HK
US
CN
SG
AU
JP
All
News
Announcements
Reports
No matches yet
Operations too frequent. Please try again later.
Please check network settings and try again Refresh
Refresh
Loading
History record
Latest News
-
Warren Buffett, the stock god: Only businesses that can be understood are good businesses, and market downturns are good opportunities.
U.S. stock market closing | Concerns over tariffs and inflation pressured the three major indexes, with the Nasdaq falling nearly 3%; Google and Palantir dropped nearly 5%; NVIDIA's "favorite child" CoreWeave's debut was a rollercoaster.
Hong Kong media: CKH HOLDINGS' plan to sell the port is postponed, and no contract will be signed next week.
Quotes
More
News
More
Learn
More
Help
More
Loading
News
More
Announcements
More
Reports
More
礼来在印度推出减肥药Mounjaro 击败诺和诺德占领主要市场
Eli Lilly and Co launched the weight loss drug Mounjaro in India, defeating Novo-Nordisk A/S to capture the major market.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Like
Views 226
Write a comment
Statement
This page is machine-translated. Futubull tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation.
Comment(0)
Reason For Report